Association between Fasting Blood Sugar Levels and Psoriasis Severity using the PASI Score: A Single-Center Cross-Sectional Study

Article Sidebar

PDF
Published: Jun 23, 2026
DOI: https://doi.org/10.62691/jmuh.2026.7829
Keywords:
fasting plasma sugar level psoriasis area and severity index psoriasis

Main Article Content

Ajiraya Saliddiphant
Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Natnaphat Boonrith
Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Nontanee Powichian
Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Charussri Leeyaphan
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
https://orcid.org/0000-0001-8430-376X
Sumanas Bunyaratavej
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
https://orcid.org/0000-0002-0852-7742

Abstract

Objectives: Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by dry, thick, raised patches. The Psoriasis Area and Severity Index (PASI) measures disease severity body surface area and treatment efficacy. Psoriasis can increase the risk of diabetes and worsen insulin resistance, resulting in increased fasting blood sugar (FBS) and worsening diabetic symptoms. This study aimed to study the correlation between FBS and PASI score in psoriasis patients.
Materials and Methods: This retrospective study analyzed the relationship between PASI scores and FBS levels in psoriasis patients who visited the Dermatology Outpatient Clinic between 2019 and 2023. PASI scores were assessed by dermatologists, and FBS levels collected within a month of PASI evaluation were analyzed. Patients were categorized into diabetes mellitus (DM) and non- diabetes mellitus (non-DM) groups. Those on systemic therapy or without FBS were excluded.
Results: Data from 65 psoriasis patients were analyzed (non-DM (n = 58), DM (n = 7)). The average PASI score was 8.4 (5.9, 10.9) in non-DM patients and 7 (2.7, 4) in DM patients, respectively. Mean FBS levels were evaluated based on PASI severity: mild (n = 36) - 109.4 (100.1, 118.8), moderate (n = 13) - 103.6 (95.9, 111.4), and severe (n = 16) - 96.8 (92.9, 100.6). Comparison of mean FBS across PASI severity categories showed no statistically significant differences (mild vs. moderate: mean difference 5.7 milligrams (mg)/ deciliter (dL), p = 0.416, 95% confidence interval (CI) −8.3 to 19.8; moderate vs. severe: mean difference 6.8 mg/dL, p = 0.402, 95% CI −9.4 to 23.1; mild vs. severe: mean difference 12.6 mg/dL, p = 0.058, 95% CI −0.4 to 25.7).
Conclusion: No significant correlation was found between FBS levels and PASI scores in either the DM or non-DM groups.

Downloads

Download data is not yet available.

Article Details

How to Cite
Saliddiphant, A. ., Boonrith, N. ., Powichian, N. ., Leeyaphan, C. ., & Bunyaratavej, S. . (2026). Association between Fasting Blood Sugar Levels and Psoriasis Severity using the PASI Score: A Single-Center Cross-Sectional Study. Journal of Medicine and Urban Health. https://doi.org/10.62691/jmuh.2026.7829
Issue
Online First
Section
Original Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles in this journal are copyrighted by the x may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.
use or modification of the articles is prohibited without permission.
statements expressed in the articles are solely the opinions of the authors.
authors are fully responsible for the content and accuracy of their articles.
other reuse or republication requires permission from the journal."

References

Nair PA, Badri T. Psoriasis. StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.

Ikumi K, Odanaka M, Shime H, Imai M, Osaga S, Taguchi O, et al. Hyperglycemia is associated with psoriatic inflammation in both humans and mice. J Invest Dermatol 2019;139(6):1329–38.e7. doi: 10.1016/j.jid.2019.01.029.

National Institute of Arthritis and Musculoskeletal and Skin Diseases. Psoriasis: symptoms, causes, & risk factors [internet]. 2023 [cited 2024 Mar 4]. Available from: https://www.niams.nih.gov/health-topics/psoriasis.

National Psoriasis Foundation. Psoriasis statistics: get the facts about psoriasis and psoriatic arthritis [internet]. 2025 [cited 2024 Mar 4]. Available from: https://www.psoriasis.org/psoriasis-statistics/#:~:text=Prevalence&text=125%20million%20people%20worldwide%20—%202,the%20World%20Psoriasis%20Day%20consortium.

Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32(6):982–6. doi: 10.1016/0190-9622(95)91336-x.

Brazzelli V, Maffioli P, Bolcato V, Ciolfi C, D’Angelo A, Tinelli C, et al. Psoriasis and diabetes, a dangerous association: evaluation of insulin resistance, lipid abnormalities, and cardiovascular risk biomarkers. Front Med (Lausanne) 2021;8:605691. doi: 10.3389/fmed.2021.605691.

Mirghani H, Altemani A, Alsaedi E, Aldawish R, Alharbi M, Alzahrani R, et al. The association of psoriasis, diabetes mellitus, and hypertension: a meta-analysis. Cureus 2023;15(11):e48855. doi: 10.7759/cureus.48855.

International Diabetes Federation. Country-level diabetes data: Thailand [internet]. 2025 [cited 2024 Mar 4]. Available from: https://diabetesatlas.org/data-by-location/country/thailand/

Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008;22(5):585–9. doi: 10.1111/j.1468-3083.2008.02636.x.

Gyldenløve M, Storgaard H, Holst JJ, Vilsbøll T, Knop FK, Skov L. Patients with psoriasis are insulin resistant. J Am Acad Dermatol 2015;72(4):599–605. doi: 10.1016/j.jaad.2015.01.004.

Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013;149(1):84–91. doi: 10.1001/2013.jamadermatol.406.

Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii65–8. doi: 10.1136/ard.2004.031237.

Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. Clin Dermatol 2010;28(1):67–72. doi: 10.1016/j.clindermatol.2009.03.001.

Clinical Practice Guideline for psoriasis [internet]. 2011 [cited 2025 Jan 29]. Available from:https://ioddev.kabintech.net/wp-content/uploads/2021/04/8062553889fcc3e93_007-Guideline_Psoriasis_2011.pdf.

Rajatanavin N, Wongpraparut C, Rattanakaemakorn P, Chularojanamontri L, Pongcharoen P, Pattamadilok B, et al. Expert opinion on psoriasis management, 2020 and beyond. Thai J Dermatol 2022;38(1):1–16.

Riley L. Mean Fasting Blood Glucose [internet]. 2024 [cited 2024 Mar 4]. Available from: https://www.who.int/data/gho/indicator-metadata-registry/imr-details/2380.

Chularojanamontri L, Kulthanan K, Suthipinittharm P, Jiamton S, Wongpraparut C, Silpa-Archa N, et al. Clinical differences between early- and late-onset psoriasis in Thai patients. Int J Dermatol 2015;54(3):290–4. doi: 10.1111/ijd.12515.

Zhang MX, Zheng BY, Chen HX, Chien CW. Clinical effects of antidiabetic drugs on psoriasis: the perspective of evidence-based medicine. World J Diabetes 2021;12(8):1141–5. doi: 10.4239/wjd.v12.i8.1141.

Good to know: factors affecting blood glucose. Clin Diabetes 2018;36(2):202. doi: 10.2337/cd18-0012.

Aekplakorn W, Satheannoppakao W, Putwatana P, Taneepanichskul S, Kessomboon P, Chongsuvivatwong V, et al. Dietary pattern and metabolic syndrome in thai adults. J Nutr Metab 2015;2015:468759. doi: 10.1155/2015/468759.

Abramczyk R, Queller JN, Rachfal AW, Schwartz SS. Diabetes and psoriasis: different sides of the same prism. Diabetes Metab Syndr Obes 2020;13:3571–7. doi: 10.2147/DMSO.S273147.